Aidan Fry
Executive Editor, Commercial/R&D
{A1EF0A44-49EE-467F-964C-F748991F5552}
+21 year(s) experience
Generics Bulletin
By Aidan Fry 06 Dec 2019
US niche generics player Teligent intends to use its expertise in topical and injectable drugs manufacturing to push into the North American ophthalmics sector.
Generics Bulletin
By Aidan Fry 20 Nov 2019
In a bid to make better use of Amneal’s US portfolio and pipeline, the company is looking for international licensing partners, especially in Eastern Europe and China, as its new management team looks to restore growth and revive profit margins.
Topic Business strategies
Generics Bulletin
By Aidan Fry 20 Nov 2019
Accord Healthcare has secured commercial rights to Adienne’s novel lyophilized formulation of thiotepa in Europe, extending its portfolio of cancer treatments.
Topic Business strategies Cancer
Generics Bulletin
By Aidan Fry 01 Nov 2019
By mid-February next year, Pfizer plans to have introduced in the US bevacizumab, rituximab and trastuzumab biosimilars to Avastin, Rituxan and Herceptin.
Generics Bulletin
By Aidan Fry 15 Aug 2019
By acquiring global rights to epinephrine and naloxone nasal spray candidates from Insys, Hikma is following its strategy of moving its non-injectable Generics business segment in the US towards differentiated products.
Topic Business strategies
Generics Bulletin
By Aidan Fry 09 Aug 2019
With Erez Israeli set to step up from COO to CEO, Dr Reddy’s is looking to leverage its lack of debt and strong cash flow in the mergers and acquisitions arena.
Topic Business strategies
Generics Bulletin
By Aidan Fry 22 Mar 2019
Abraxis’ attempt to obtain a UK SPC for its Abraxane formulation of the known active ingredient paclitaxel has been thwarted by the CJEU.
Topic BioPharmaceutical
Pink Sheet
23 Aug 2019
Pink Sheet
04 Apr 2019
Scrip
14 Mar 2019